{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:47Z","timestamp":1792783427091,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"PPD Evidera Patient Centered Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40271-025-00795-x","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:33:21Z","timestamp":1770028401000},"page":"385-405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Beyond Numbers: Uses and Value of In-Trial Interview Data for Regulatory and Health Technology Assessment (HTA) Decision Making"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4701-8825","authenticated-orcid":false,"given":"Carla","family":"Dias-Barbosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Rolska-Wojcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1985-4826","authenticated-orcid":false,"given":"Karen","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-2738","authenticated-orcid":false,"given":"Olabimpe R.","family":"Eseyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6899-2139","authenticated-orcid":false,"given":"Mona L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"8","key":"795_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jval.2025.05.002","volume":"28","author":"M Krol","year":"2025","unstructured":"Krol M, Maher J, Halmos T, Reaney M, Shana\u2019a A, Arnould B, et al. The Increasing Use of Clinical Outcome Assessments in US Food and Drug Administration Labels and the German Gemeinsamer Bundesausschuss, National Institute for Health and Care Excellence, and the French Haute Autorite de Sante Assessments From 2012 to 2022. Value Health. 2025;28(8):1195\u2013203.","journal-title":"Value Health."},{"key":"795_CR2","unstructured":"Food and Drug Administration. Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products. Guidance for Industry. 2019 [cited 2025 August 14]; Available from: https:\/\/www.fda.gov\/media\/133660\/download."},{"issue":"2","key":"795_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70113","volume":"11","author":"T Buracchio","year":"2025","unstructured":"Buracchio T, Campbell M, Krudys K. Assessing clinical meaningfulness in clinical trials for Alzheimer\u2019s disease: a U.S. regulatory perspective. Alzheimers Dement (N Y). 2025;11(2):e70113.","journal-title":"Alzheimers Dement (N Y)."},{"key":"795_CR4","unstructured":"Food and Drug Administration. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. March 21, 2025 [cited 2025 July 10]; Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical."},{"key":"795_CR5","unstructured":"Food and Drug Administration. Qualitative techniques to define meaningful within-patient change in symptoms of advanced cancer patients. May 17, 2023 [cited 2025 July 10]; Available from: https:\/\/www.fda.gov\/science-research\/advancing-regulatory-science\/qualitative-techniques-define-meaningful-within-patient-change-symptoms-advanced-cancer-patients."},{"key":"795_CR6","unstructured":"Food and Drug Administration. Patient-Focused Drug Development Glossary. 2018 [cited 2025 August 14]; Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/patient-focused-drug-development-glossary#:~:text=1,see%20section%203002(b)."},{"key":"795_CR7","unstructured":"Federal Register. Patient-Focused Drug Development: Workshop To Discuss Methodologic and Other Challenges Related to Patient Experience Data; Public Workshop; Request for Comments. 2024 [cited 2025 August 14]; Available from: https:\/\/www.federalregister.gov\/documents\/2024\/11\/14\/2024-26399\/patient-focused-drug-development-workshop-to-discuss-methodologic-and-other-challenges-related-to."},{"key":"795_CR8","unstructured":"Food and Drug Administration. Patient-Focused Drug Development: Workshop to Discuss Methodologic and Other Challenges Related to Patient Experience Data. 2024 [cited 2025 August 14]; Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/patient-focused-drug-development-workshop-discuss-methodologic-and-other-challenges-related-patient."},{"key":"795_CR9","unstructured":"European Medicines Agency. EMA regulatory science to 2025: strategic reflection. [cited 2025 July 10]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ema-regulatory-science-2025-strategic-reflection_en.pdf."},{"key":"795_CR10","unstructured":"Vaidya P. How soon is too soon? Enhancing early regulatory engagement and harmonization to streamline patient-focused drug development. In: 2025: DIA; 2025."},{"key":"795_CR11","unstructured":"European Medicines Agency (EMA). Patient experience data (PED) reflection paper. 2025 [cited 2025 October 23]; Available from: https:\/\/www.ema.europa.eu\/en\/patient-experience-data-ped-reflection-paper"},{"issue":"11","key":"795_CR12","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.clinthera.2017.09.013","volume":"39","author":"L Anthony","year":"2017","unstructured":"Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, et al. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158\u201368.","journal-title":"Clin Ther"},{"key":"795_CR13","doi-asserted-by":"publisher","first-page":"1274659","DOI":"10.3389\/fonc.2023.1274659","volume":"13","author":"A Cardellino","year":"2023","unstructured":"Cardellino A, Correll JR, Martin M, Gorsh B, Sapra S, Popat R. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed\/refractory multiple myeloma in the DREAMM-2 study. Front Oncol. 2023;13:1274659.","journal-title":"Front Oncol"},{"key":"795_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/PROM.S385542","volume":"14","author":"S Clinch","year":"2023","unstructured":"Clinch S, Hudgens S, Gibbons E, Willgoss T, Smith J, Polek E, et al. Quantitative and qualitative exploration of meaningful change on the vineland adaptive behavior scales (Vineland-II) in children and adolescents with autism without intellectual disability following participation in a clinical trial. Patient Relat Outcome Meas. 2023;14:337\u201354.","journal-title":"Patient Relat Outcome Meas"},{"issue":"11","key":"795_CR15","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.clinthera.2019.09.003","volume":"41","author":"C Ervin","year":"2019","unstructured":"Ervin C, Joish VN, Evans E, DiBenedetti D, Reaney M, Preblick R, et al. Insights into patients\u2019 experience with type 1 diabetes: exit interviews from phase III studies of sotagliflozin. Clin Ther. 2019;41(11):2219\u201330.","journal-title":"Clin Ther"},{"issue":"12","key":"795_CR16","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1007\/s12325-017-0632-6","volume":"34","author":"CM Ervin","year":"2017","unstructured":"Ervin CM, Reasner DS, Hanlon JT, Fehnel SE. Exploring the diabetic gastroparesis patient experience: patient exit interviews. Adv Ther. 2017;34(12):2680\u201392.","journal-title":"Adv Ther"},{"issue":"4","key":"795_CR17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.clinthera.2016.03.002","volume":"38","author":"HL Gelhorn","year":"2016","unstructured":"Gelhorn HL, Kulke MH, O\u2019Dorisio T, Yang QM, Jackson J, Jackson S, et al. Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: a qualitative interview approach. Clin Ther. 2016;38(4):759\u201368.","journal-title":"Clin Ther"},{"issue":"4","key":"795_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1089\/jwh.2020.8460","volume":"30","author":"P Koochaki","year":"2021","unstructured":"Koochaki P, Revicki D, Wilson H, Pokrzywinski R, Jordan R, Lucas J, et al. The patient experience of premenopausal women treated with bremelanotide for hypoactive sexual desire disorder: RECONNECT exit study results. J Womens Health (Larchmt). 2021;30(4):587\u201395.","journal-title":"J Womens Health (Larchmt)"},{"issue":"5","key":"795_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40271-019-00369-8","volume":"12","author":"S Lewis","year":"2019","unstructured":"Lewis S, Romano C, De Bruecker G, Murrough JW, Shelton R, Singh JB, et al. Analysis of clinical trial exit interview data in patients with treatment-resistant depression. Patient. 2019;12(5):527\u201337.","journal-title":"Patient"},{"issue":"3","key":"795_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40271-022-00578-8","volume":"15","author":"LS Matza","year":"2022","unstructured":"Matza LS, Stewart KD, Lando LF, Patel H, Boye KS. Exit interviews examining the patient experience in clinical trials of tirzepatide for treatment of type 2 diabetes. Patient. 2022;15(3):367\u201377.","journal-title":"Patient"},{"key":"795_CR21","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Filipenko D, Dias Barbosa C, Rodriguez D, Chambenoit O, Jack K, et al. Patients' experiences of atopic dermatitis and nemolizumab treatment: an in-trial interview study embedded in a phase 3 clinical trial (ARCADIA). Patient. 2025;18(5):511\u2013521.","DOI":"10.1007\/s40271-025-00741-x"},{"issue":"4","key":"795_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaad.2020.06.991","volume":"84","author":"M Vernon","year":"2021","unstructured":"Vernon M, Stander S, Munera C, Spencer RH, Menzaghi F. Clinically meaningful change in itch intensity scores: an evaluation in patients with chronic kidney disease-associated pruritus. J Am Acad Dermatol. 2021;84(4):1132\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"795_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41687-019-0100-y","volume":"3","author":"H Staunton","year":"2019","unstructured":"Staunton H, Willgoss T, Nelsen L, Burbridge C, Sully K, Rofail D, et al. An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. J Patient Rep Outcomes. 2019;3(1):16.","journal-title":"J Patient Rep Outcomes."},{"key":"795_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1197529","volume":"10","author":"AS Michel","year":"2023","unstructured":"Michel AS, Kamudoni P, Marrel A, Adiutori R, Desvignes-Gleizes C, Lanar S, et al. Integrating qualitative interviews in drug development and the use of qualitative evidence in product labelling and health technology assessments: a review. Front Med (Lausanne). 2023;10:1197529.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"795_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/2374373519830743","volume":"7","author":"V Rezash","year":"2020","unstructured":"Rezash V, Reed J, Gedeon B, Parsons E, Siedlecki S, Daniels B, et al. Who needs what? Perceptions of patients and caregivers in oncology phase 1 trials. J Patient Exp. 2020;7(1):27\u201333.","journal-title":"J Patient Exp"},{"issue":"1","key":"795_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40257-022-00733-9","volume":"24","author":"JC Browning","year":"2023","unstructured":"Browning JC, Cartwright M, Thorla I Jr, Martin SA, Olayinka-Amao O, Maeda-Chubachi T. A patient-centered perspective of molluscum contagiosum as reported by B-SIMPLE4 clinical trial patients and caregivers: global impression of change and exit interview substudy results. Am J Clin Dermatol. 2023;24(1):119\u201333.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"795_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13023-018-0835-1","volume":"13","author":"M Bharmal","year":"2018","unstructured":"Bharmal M, Guillemin I, Marrel A, Arnould B, Lambert J, Hennessy M, et al. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial. Orphanet J Rare Dis. 2018;13(1):95.","journal-title":"Orphanet J Rare Dis"},{"key":"795_CR28","unstructured":"HealthMeasures. Home page. March 23, 2023 [cited 2025 July 10]; Available from: https:\/\/www.healthmeasures.net\/."},{"key":"795_CR29","unstructured":"European Organisation for Research and Treatment of Cancer. Home page. [cited 2025 July 10]; Available from: https:\/\/www.eortc.org\/."},{"key":"795_CR30","unstructured":"The FACIT Group. Home page. [cited 2025 July 10]; Available from: https:\/\/www.facit.org\/."},{"issue":"1","key":"795_CR31","volume":"40","author":"SM Szabo","year":"2023","unstructured":"Szabo SM, Hawkins NS, Germeni E. The extent and quality of qualitative evidence included in health technology assessments: a review of submissions to NICE and CADTH. Int J Technol Assess Health Care. 2023;40(1):e6.","journal-title":"Int J Technol Assess Health Care"},{"key":"795_CR32","unstructured":"Food and Drug Administration. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input. 2018 [cited 2025 August 14]; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input."},{"key":"795_CR33","unstructured":"Food and Drug Administration. Patient-Focused Drug Development: Methods to Identify What Is Important to Patients. 2022 [cited 2025 August 14]; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients."},{"key":"795_CR34","unstructured":"Food and Drug Administration. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. 2022 [cited 2025 October 27]; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome."},{"key":"795_CR35","unstructured":"Food and Drug Administration. Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making. 2023 [cited 2025 August 14]; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory."},{"key":"795_CR36","unstructured":"Food and Drug Administration. Core patient-reported outcomes in cancer clinical trials. October 17, 2024 [cited 2025 July 10]; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/core-patient-reported-outcomes-cancer-clinical-trials."},{"key":"795_CR37","unstructured":"Food and Drug Administration. Rare diseases: considerations for the development of drugs and biological products. December 21, 2023 [cited 2025 July 10]; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-considerations-development-drugs-and-biological-products."},{"key":"795_CR38","unstructured":"Food and Drug Administration. Human gene therapy for rare diseases: guidance for industry. [cited 2025 July 10]; Available from: https:\/\/www.fda.gov\/media\/113807\/download."},{"key":"795_CR39","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. General Methods. 2023 [cited 2025 August 14]; Available from: https:\/\/www.iqwig.de\/methoden\/general-methods_version-7-0.pdf."},{"issue":"3","key":"795_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40271-024-00726-2","volume":"18","author":"N Williamson","year":"2025","unstructured":"Williamson N, Howse C, Hodson N, Stein J, Arbuckle R. Qualitative in-trial interviews: methods, challenges, and best practice. Patient Patient-Centered Outcomes Res. 2025;18(3):199\u2013209.","journal-title":"Patient Patient-Centered Outcomes Res"},{"key":"795_CR41","unstructured":"Ring N, Ritchie K, Mandava L, Japson R. A guide to synthesising qualitative research for researchers undertaking health technology assessments and systematic reviews. [cited 2025 July 10]; Available from: https:\/\/dspace.stir.ac.uk\/bitstream\/1893\/3205\/1\/HTA_MethodsofSynthesisingQualitativeLiterature_DEC101.pdf."},{"key":"795_CR42","unstructured":"Haute Autorite de Sante. Real-world studies for the evaluation of medicines and medical devices. 2021 [cited 2025 August 14]; Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-06\/guide_etude_en_vie_reelle_medicaments__dm.pdf."},{"key":"795_CR43","unstructured":"Agenzia Italiana del Farmaco. Guidelines for the preparation of the dossier in support of the application for reimbursement and pricing of a medicinal product pursuant to Ministerial Decree of 2 August 2019. 2020 [cited 2025 August 14]; Available from: https:\/\/www.aifa.gov.it\/documents\/20142\/1283800\/Linee_guida_dossier_domanda_rimborsabilita.pdf\/8249e3d6-b2fc-915d-a211-02abafb8aa6d."},{"key":"795_CR44","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Standard Operating Procedure for Clinical Evaluation, Economic Evaluation, and Therapeutic Positioning for the Preparation of Therapeutic Positioning Reports of Medicines in the National Health System. 2020 [cited 2025 August 14]; Available from: https:\/\/www.sanidad.gob.es\/areas\/farmacia\/infoMedicamentos\/IPT\/docs\/20200708.PNT_elaboracion_IPT_CPF8Julio.pdf."},{"key":"795_CR45","unstructured":"National Institute for Health and Care Excellence. Final evaluation document. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations. 2019 [cited 2025 August 14]; Available from: https:\/\/www.nice.org.uk\/guidance\/hst11\/documents\/final-evaluation-determination-document-2."},{"key":"795_CR46","doi-asserted-by":"publisher","DOI":"10.3768\/rtipress.2018.op.0054.1808","volume-title":"conducting patient interviews within a clinical trial setting","author":"DB DiBenedetti","year":"2018","unstructured":"DiBenedetti DB, Brown T, Romano C, Ervin C, Lewis S, Fehnel SE. conducting patient interviews within a clinical trial setting. Research Triangle Park: RTI Press; 2018."},{"issue":"8","key":"795_CR47","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1524-4733.2009.00603.x","volume":"12","author":"M Rothman","year":"2009","unstructured":"Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report. Value Health. 2009;12(8):1075\u201383.","journal-title":"Value Health"},{"issue":"8","key":"795_CR48","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"issue":"5","key":"795_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232076","volume":"15","author":"G Guest","year":"2020","unstructured":"Guest G, Namey E, Chen M. A simple method to assess and report thematic saturation in qualitative research. PLoS ONE. 2020;15(5):e0232076.","journal-title":"PLoS ONE"},{"issue":"2","key":"795_CR50","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jval.2016.12.010","volume":"20","author":"FB Kristensen","year":"2017","unstructured":"Kristensen FB, Lampe K, Wild C, Cerbo M, Goettsch W, Becla L. The HTA Core Model\u00ae\u201410 years of developing an international framework to share multidimensional value assessment. Value in Health. 2017;20(2):244\u201350.","journal-title":"Value in Health."},{"key":"795_CR51","doi-asserted-by":"crossref","unstructured":"O'Cathain A, Thomas KJ, Drabble SJ, Rudolph A, Hewison J. What can qualitative research do for randomised controlled trials? A systematic mapping review. BMJ Open. 2013;3(6).","DOI":"10.1136\/bmjopen-2013-002889"},{"key":"795_CR52","unstructured":"Sepodes B, Burgos JG. Reinforce patient relevance in evidence generation. [cited 2025 July 10]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/presentation\/presentation-ema-regulatory-science-2025-reinforce-patient-relevance-evidence-generation_en.pdf."},{"key":"795_CR53","unstructured":"Booth A. A methodological update on the use of qualitative evidence in health technology assessment. [cited 2025 July 10]; Available from: https:\/\/www.sheffield.ac.uk\/media\/34045\/download?attachment."},{"key":"795_CR54","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. May 13, 2025 [cited 2025 July 10]; Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation."},{"issue":"3","key":"795_CR55","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"issue":"2","key":"795_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.healthpol.2018.12.003","volume":"123","author":"O Efthymiadou","year":"2019","unstructured":"Efthymiadou O, Mossman J, Kanavos P. Health related quality of life aspects not captured by EQ-5D-5L: results from an international survey of patients. Health Policy. 2019;123(2):159\u201365.","journal-title":"Health Policy"},{"issue":"3","key":"795_CR57","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40271-024-00683-w","volume":"17","author":"A Gnanasakthy","year":"2024","unstructured":"Gnanasakthy A, DeMuro CR. The limitations of EQ-5D as a clinical outcome assessment tool. Patient. 2024;17(3):215\u20137.","journal-title":"Patient"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00795-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-025-00795-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00795-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:14Z","timestamp":1777387574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-025-00795-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["795"],"URL":"https:\/\/doi.org\/10.1007\/s40271-025-00795-x","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees of PPD\u2122 Evidera\u2122 Patient-Centered Research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"CD, MK, PWR, MM were involved in the conception of the study. All authors were involved in the analysis, interpretation and manuscript writing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}